Yeon Sung Son

Title: Yeon Sung Son: Innovator in Cholangiocarcinoma Treatment

Introduction

Yeon Sung Son is a prominent inventor based in Seoul, South Korea. He has made significant contributions to the field of biotechnology, particularly in the treatment of cholangiocarcinoma, a type of cancer that affects the bile ducts. His innovative work has the potential to improve the lives of many patients suffering from this challenging disease.

Latest Patents

Yeon Sung Son holds a patent for a pharmaceutical composition aimed at treating cholangiocarcinoma. This patent includes a method for inhibiting the growth or invasion of cholangiocarcinoma. The composition comprises an L1CAM activity inhibitor or expression suppressor. The findings indicate that L1CAM is overexpressed in cholangiocarcinoma and plays a crucial role in the growth and metastasis of the disease. The patent outlines that antibodies that inhibit L1CAM activity or siRNAs that suppress its expression can significantly reduce the growth and invasion of cholangiocarcinoma cells.

Career Highlights

Yeon Sung Son is affiliated with the Korea Research Institute of Bioscience and Biotechnology. His work has been instrumental in advancing the understanding of cholangiocarcinoma and developing targeted therapies. His research has garnered attention for its potential to change treatment protocols for this aggressive cancer.

Collaborations

Yeon Sung Son has collaborated with notable colleagues, including Hyo Jeong Hong and Jung-Whoi Lee. Their combined expertise has contributed to the success of their research initiatives and the development of innovative treatment options.

Conclusion

Yeon Sung Son's contributions to the field of cancer treatment, particularly for cholangiocarcinoma, highlight the importance of innovation in biotechnology. His patent and ongoing research efforts represent a significant step forward in the fight against this challenging disease.